Lebrikizumab is a humanised monoclonal antibody that targets and inhibits interleukin 13 (IL-13), thereby suppressing Th2 inflammation. It is mainly used in the study of asthma and atopic dermatitis.
Purity:
95.00%
CAS Number:
[953400-68-5]
Target:
IL Receptor|||Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted